Intestinal cholesterol secretion: Future clinical implications

Netherlands Journal of Medicine

Volumn 71, Issue 9, 2013, Pages 459-465

  Jakulj, L ^a   Besseling, J ^a   Stroes, E S G ^a   Groen, A K ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cardiovascular disease; Intestine; Reverse cholesterol transport

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER G5; ABC TRANSPORTER G8; ANTISENSE OLIGONUCLEOTIDE; CHOLESTEROL; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER X RECEPTOR; LIVER X RECEPTOR AGONIST; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHYTOSTEROL; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; SMALL INTERFERING RNA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTERIAL WALL THICKNESS; CARDIOVASCULAR RISK; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; EXCRETION; HUMAN; INTESTINAL SECRETION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; STEROL EXCRETION; TRANS INTESTINAL CHOLESTEROL EXCRETION;

ANIMALS; BIOLOGICAL MARKERS; BIOLOGICAL TRANSPORT; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, LDL; HUMANS; INTESTINES; MICE; NETHERLANDS; PROPROTEIN CONVERTASES; RISK FACTORS;

EID: 84887533241     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-81.
2. Wright RS. Recent clinical trials evaluating benefit of drug therapy for modification of HDL cholesterol. Cur Opin Cardiol. 2013;28:389-98.
3. Bosch N, Frishman WH. Newer Therapeutic Strategies to Alter HDL Level and Function. Cardiol Rev. 2013 May 23.
4. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79:8-15.
5. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 1996;124(Suppl):S11-20.
6. deGoma EM, DeGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol. 2008;51:2199-211.
7. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. New Engl J Med. 2007;357:2109-22.
8. Briel M, Ferreira-Gonzalez I, You JJ, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ. 2009;338:b92.
9. Boden WE, Probstfield JL, Anderson T, et al. Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. New Engl J Med. 2011;365:2255-67.
10. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. New Engl J Med. 2012;367:2089-99.
11. Glomset JA. The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res. 1968;9:155-67.
12. Groen AK, Bloks VW, Bandsma RH, Ottenhoff R, Chimini G, Kuipers F. Hepatobiliary cholesterol transport is not impaired in Abca1-null mice lacking HDL. J Clin Invest. 2001;108:843-50.
13. Jolley CD, Woollett LA, Turley SD, Dietschy JM. Centripetal cholesterol flux to the liver is dictated by events in the peripheral organs and not by the plasma high density lipoprotein or apolipoprotein A-I concentration. J Lipid Res. 1998;39:2143-9.
14. Xie C, Turley SD, Dietschy JM. ABCA1 plays no role in the centripetal movement of cholesterol from peripheral tissues to the liver and intestine in the mouse. J Lipid Res. 2009;50:1316-29.
15. Harchaoui K El, Franssen R, Hovingh GK, et al. Reduced fecal sterol excretion in subjects with familial hypoalphalipoproteinemia. Atherosclerosis. 2009;207:614-6.
16. Eriksson M, Carlson LA, Miettinen TA, Angelin B. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation. 1999;100:594-8.
17. Nanjee MN, Cooke CJ, Garvin R, et al. Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J Lipid Res. 2001;42:1586-93.
18. Holleboom AG, Jakulj L, Franssen R, et al. In vivo tissue cholesterol efflux is reduced in carriers of a mutation in APOA1. J Lipid Res. 2013;54:1964-71.
19. Berge KE, Tian H, Graf GA, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science. 2000;290:1771-5.
20. Yu L, Hammer RE, Li-Hawkins J, et al. Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion. Proc Natl Acad Sci U S A. 2002;99:16237-42.
21. Plõsch T, Kok T, Bloks VW, et al. Increased hepatobiliary and fecal cholesterol excretion upon activation of the liver X receptor is independent of ABCA1. J Biol Chem. 2002;277:33870-7.
22. Temel RE, Tang W, Ma Y, et al. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest. 2007;117:1968-78.
23. Kruit JK, Plösch T, Havinga R, et al. Increased fecal neutral sterol loss upon liver X receptor activation is independent of biliary sterol secretion in mice. Gastroenterology. 2005;128:147-56.
24. Schwarz M, Russell DW, Dietschy JM, Turley SD. Marked reduction in bile acid synthesis in cholesterol 7alpha-hydroxylase-deficient mice does not lead to diminished tissue cholesterol turnover or to hypercholesterolemia. J Lipid Res. 1998;39:1833-43.
25. Brown JM, Bell TA, Alger HM, et al. Targeted depletion of hepatic ACAT2-driven cholesterol esterification reveals a non-biliary route for fecal neutral sterol loss. J Biol Chem. 2008;283:10522-34.
26. Sperry W. Lipid Excretion IV. A study of the relationship of the bile to the fecal lipids with special reference to certain problems of sterol metabolism. J Biol Chem. 1927;71:351-78.
27. Pertsemlidis D, Kirchman EH, Ahrens EH. Regulation of cholesterol metabolism in the dog. I. Effects of complete bile diversion and of cholesterol feeding on absorption, synthesis, accumulation, and excretion rates measured during life. J Clin Invest. 1973;52:2353-67.
28. Dietschy JM, Siperstein MD. Cholesterol synthesis by the gastrointestinal tract: localization and mechanisms of control. J Clin Invest. 1965;44:1311-27.
29. Bandsma RH, Stellaard F, Vonk RJ, et al. Contribution of newly synthesized cholesterol to rat plasma and bile determined by mass isotopomer distribution analysis: bile-salt flux promotes secretion of newly synthesized cholesterol into bile. Biochem J. 1998;329(Pt 3):699-703.
30. Van der Velde AE, Vrins CLJ, van den Oever K, et al. Direct intestinal cholesterol secretion contributes significantly to total fecal neutral sterol excretion in mice. Gastroenterology. 2007;133:967-75.
31. Van der Veen JN, van Dijk TH, Vrins CLJ, et al. Activation of the liver X receptor stimulates trans-intestinal excretion of plasma cholesterol. J Biol Chem. 2009;284:19211-9.
32. Van der Velde AE, Vrins CLJ, van den Oever K, et al. Regulation of direct transintestinal cholesterol excretion in mice. Am J Physiol Gastrointest Liver Physiol. 2008;295:G203-G208.
33. Temel RE, Sawyer JK, Yu L, et al. Biliary sterol secretion is not required for macrophage reverse cholesterol transport. Cell Metab. 2010;12:96-102.
34. Nijstad N, Gautier T, Briand F, Rader DJ, Tietge UJF. Biliary sterol secretion is required for functional in vivo reverse cholesterol transport in mice. Gastroenterology. 2011;140:1043-51.
35. Temel RE, Brown JM. Biliary and nonbiliary contributions to reverse cholesterol transport. Curr Opin Lipidol. 2012;23:85-90.
36. Brufau G, Groen AK, Kuipers F. Reverse cholesterol transport revisited: contribution of biliary versus intestinal cholesterol excretion. Arterioscler Thromb Vasc Biol. 2011;31:1726-33.
37. Van der Velde AE, Brufau G, Groen AK. Transintestinal cholesterol efflux. Curr Opin Lipidol. 2010;21:167-71.
38. Vrins CLJ, Ottenhoff R, van den Oever K, et al. Trans-intestinal cholesterol efflux is not mediated through high density lipoprotein. J Lipid Res. 2012;53:2017-23.
39. Stange EF, Dietschy JM. Cholesterol synthesis and low density lipoprotein uptake are regulated independently in rat small intestinal epithelium. Proc Natl Acad Sci U S A. 1983;80:5739-43.
40. Le May C, Berger JM, Lespine A, et al. Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1. Arterioscler Thromb Vasc Biol. 2013;33:1484-93.
41. Jakulj L, Vissers MN, van Roomen CP, et al. Ezetimibe stimulates faecal neutral sterol excretion depending on abcg8 function in mice. FEBS Lett. 2010;584:3625-8.
42. Yu L, York J, von Bergmann K, Lutjohann D, Cohen JC, Hobbs HH. Stimulation of cholesterol excretion by the liver X receptor agonist requires ATP-binding cassette transporters G5 and G8. J Biol Chem. 2003;278:15565-70.
43. Brufau G, Kuipers F, Lin Y, Trautwein EA, Groen AK. A reappraisal of the mechanism by which plant sterols promote neutral sterol loss in mice. PloS One. 2011;6:e21576.
44. Yamanashi Y, Takada T, Shoda J-I, Suzuki H. Novel function of Niemann-Pick C1-like 1 as a negative regulator of Niemann-Pick C2 protein. Hepatology. 2012;55:953-64.
45. Yamanashi Y, Takada T, Yoshikado T, Shoda J-I, Suzuki H. NPC2 regulates biliary cholesterol secretion via stimulation of ABCG5/G8-mediated cholesterol transport. Gastroenterology. 2011;140:1664-74.
46. Stanley M, Pineda E, Cheng S. Serum cholesterol esters and intestinal cholesterol secretion and absorption in obstructive jaundice due to cancer. New Engl J Med. 1959;261:368-73.
47. Cheng S, Stanley M. Secretion of cholesterol by intestinal mucosa in patients with complete common bile duct obstruction. Proc Soc Exp Biol Med. 1959;101:223-5.
48. Simmonds WJ, Hofmann AF, Theodor E. Absorption of cholesterol from a micellar solution: intestinal perfusion studies in man. J Clin Invest. 1967;46:874-90.
49. Deckelbaum RJ, Lees RS, Small DM, Hedberg SE, Grundy SM. Failure of complete bile diversion and oral bile acid therapy in the treatment of homozygous familial hypercholesterolemia. New Engl J Med. 1977;296:465-70.
50. Rosenfeld R, Hellman L. The relation of plasma and biliary cholesterol to bile acid synthesis in man. J Clin Invest. 1959;38:1334-8.
51. Hellman L, Rosenfeld R, Eidinoff M, et al. Isotopic studies of plasma cholesterol of endogenous and exogenous origins. J Clin Invest. 1955;34:48-60.
52. Stellaard F, Sackmann M, Sauerbruch T, Paumgartner G. Simultaneous determination of cholic acid and chenodeoxycholic acid pool sizes and fractional turnover rates in human serum using 13C-labeled bile acids. J Lipid Res. 1984;25:1313-9.
53. Jakulj L, Mohammed H, van Dijk TH, et al. Plasma plant sterols serve as poor markers of cholesterol absorption in man. J Lipid Res. 2013;54:1144-50.
54. Im S-S, Osborne TF. Liver x receptors in atherosclerosis and inflammation. Circ Res. 2011;108:996-1001.
55. Calkin AC, Tontonoz P. Liver x receptor signaling pathways and atherosclerosis. Arterioscler Thromb Vasc Biol. 2010;30:1513-8.
56. Bonamassa B, Moschetta A. Atherosclerosis: lessons from LXR and the intestine. Trends Endocrinol Metab. 2013;24:120-8.
57. Lo Sasso G, Murzilli S, Salvatore L, e t a l. I ntestinal s pecific L XR activation stimulates reverse cholesterol transport and protects from atherosclerosis. Cell Metab. 2010;12:187-93.
58. Yasuda T, Grillot D, Billheimer JT, et al. Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in vivo. Arterioscler Thromb Vasc Biol. 2010;30:781-6.
59. Sudhop T, Lütjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002;106:1943-8.
60. Davis HR, Zhu L-J, Hoos LM, et al. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem. 2004;279:33586-92.
61. Sehayek E, Hazen SL. Cholesterol absorption from the intestine is a major determinant of reverse cholesterol transport from peripheral tissue macrophages. Arterioscler Thromb Vasc Biol. 2008;28:1296-7.
62. Briand F, Naik SU, Fuki I, et al. Both the peroxisome proliferatoractivated receptor delta agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal reabsorption of HDL-derived cholesterol. Clin Transl Sci. 2009;2:127-33.
63. Tang W, Ma Y, Jia L, Ioannou YA, Davies JP, Yu L. Genetic inactivation of NPC1L1 protects against sitosterolemia in mice lacking ABCG5/ABCG8. J Lipid Res. 2009;50:293-300.
64. Vrins CLJ, van der Velde AE, van den Oever K, et al. Peroxisome proliferator-activated receptor delta activation leads to increased transintestinal cholesterol efflux. J Lipid Res. 2009;50:2046-54.
65. Wang HH, Portincasa P, Mendez-Sanchez N, Uribe M, Wang DQ-H. Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones. Gastroenterology. 2008;134:2101-10.
66. Zúñiga S, Molina H, Azocar L, et al. Ezetimibe prevents cholesterol gallstone formation in mice. Liver Int. 2008;28:935-47.
67. Davis HR, Lowe RS, Neff DR. Effects of ezetimibe on atherosclerosis in preclinical models. Atherosclerosis. 2011;215:266-78.
68. Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New Engl J Med. 2008;358:1431-43.
69. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. New Engl J Med. 2009;361:2113-22.
70. Bogiatzi C, Spence JD. Ezetimibe and regression of carotid atherosclerosis: importance of measuring plaque burden. Stroke. 2012;43:1153-5.
71. Villines TC, Stanek EJ, Devine PJ, et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol. 2010;55:2721-6.
72. Engelking LJ, McFarlane MR, Li CK, Liang G. Blockade of cholesterol absorption by ezetimibe reveals a complex homeostatic network in enterocytes. J Lipid Res. 2012;53:1359-68.
73. Descamps OS, De Sutter J, Guillaume M, Missault L. Where does the interplay between cholesterol absorption and synthesis in the context of statin and/or ezetimibe treatment stand today? Atherosclerosis. 2011;217:308-21.
74. Califf RM, Lokhnygina Y, Cannon CP, et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. Am Heart J. 2010;159:705-9.
75. Petrides F, Shearston K, Chatelais M, Guilbaud F, Meilhac O, Lambert G. The promises of PCSK9 inhibition. Curr Opin Lipidol. 2013;24:307-12.
76. Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. New Engl J Med. 2006;354:1264-72.
77. Levy E, Ben Djoudi Ouadda A, Spahis S, et al. PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells. Atherosclerosis. 2013;227:297-306.
78. Salen G, Ahrens EH, Grundy SM. Metabolism of beta-sitosterol in man. J Clin Invest. 1970;49:952-67.
79. O'Neill FH, Sanders TAB, Thompson GR. Comparison of efficacy of plant stanol ester and sterol ester: short-term and longer-term studies. Am J Cardiol. 2005;96:29D-36D.
80. McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006;97:89C-94C.
81. Jones PJ, Raeini-Sarjaz M, Ntanios FY, Vanstone CA, Feng JY, Parsons WE. Modulation of plasma lipid levels and cholesterol kinetics by phytosterol versus phytostanol esters. J Lipid Res. 2000;41:697-705.
82. Calpe-Berdiel L, Escolà-Gil JC, Blanco-Vaca F. New insights into the molecular actions of plant sterols and stanols in cholesterol metabolism. Atherosclerosis. 2009;203:18-31.
83. Racette SB, Lin X, Lefevre M, et al. Dose effects of dietary phytosterols on cholesterol metabolism: a controlled feeding study. Am J Clin Nutr. 2010;91:32-8.
84. Kaneko E, Matsuda M, Yamada Y, Tachibana Y, Shimomura I, Makishima M. Induction of intestinal ATP-binding cassette transporters by a phytosterol-derived liver X receptor agonist. J Biol Chem. 2003;278:36091-8.
85. Plat J, Mensink RP. Increased intestinal ABCA1 expression contributes to the decrease in cholesterol absorption after plant stanol consumption. FASEB J. 2002;16:1248-53.
86. Calpe-Berdiel L, Escolà-Gil JC, Julve J, Zapico-Muñiz E, Canals F, Blanco-Vaca F. Differential intestinal mucosal protein expression in hypercholesterolemic mice fed a phytosterol-enriched diet. Proteomics. 2007;7:2659-66.